GB2119246A - Solid shaped articles - Google Patents

Solid shaped articles Download PDF

Info

Publication number
GB2119246A
GB2119246A GB08232189A GB8232189A GB2119246A GB 2119246 A GB2119246 A GB 2119246A GB 08232189 A GB08232189 A GB 08232189A GB 8232189 A GB8232189 A GB 8232189A GB 2119246 A GB2119246 A GB 2119246A
Authority
GB
United Kingdom
Prior art keywords
composition
mould
chemical
shaped article
solid shaped
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08232189A
Other versions
GB2119246B (en
Inventor
George Keith Emerson Gregory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
John Wyeth and Brother Ltd
Original Assignee
John Wyeth and Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wyeth and Brother Ltd filed Critical John Wyeth and Brother Ltd
Publication of GB2119246A publication Critical patent/GB2119246A/en
Application granted granted Critical
Publication of GB2119246B publication Critical patent/GB2119246B/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/34Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Description

1 GB2119246A 1
SPECIFICATION
Solid shaped articles This invention relates to a solid shaped article carrying a predetermined unit quantity of chemical and to a novel process for preparing such an article.
It is known to produce shaped articles carrying chemicals by a process involving sublimation of a solvent from a composition in the solid state comprising the chemical and a solution in a solvent of a carrier material. Such a process is described, for example, in our French Specification No. 7729663 (publication 2366835) and in our UK Patent Specification 1,548,022. The process generally involves freezing the composition in a mould and then freeze drying the frozen composition. The mould can be, for example, a depression in a metal plate but it is preferably a depression in a sheet of filmic material. The filmic material preferably contains more than one depression. The filmic material may be similar to that employed in conventional blister packs which are used for packaging oral contraceptive tablets and like medicament forms. 15 For example the filmic material may be made of thermoplastic material with the depressions formed by thermoforming. The preferred filmic material is a polyvinyl chloride film. Laminates such as polyvinyl chloride/ polyvinylid ine chloride, polyvinyl chloride/polytetrafluoroethylene or polyvinyl chloride/ polyvinylidene chloride/ polyethylene may also be used.
Our investigations of the process described in the above mentioned specifications have shown 20 that one of the rate limiting steps in the production of the shaped article, especially on a commercial scale, is the time required for sublimation of the solvent in the freeze drying apparatus. We have found that the drying time can be reduced substantially if the depth of the composition in the mould (prior to freezing) is kept to a minimum. In general, drying times tend to be proportional to the square of the thickness. We have found that if the mean depth of composition in the mould is about 4.0 mm or less (preferably about 3.5 mm or less) reasonable drying times can be attained. However, when shaped articles of this mean thickness were produced in conventional moulds with substantially vertical side walls, there was considerable variation in thickness in each sample if the moulds were not completely filled. The shaped articles in general had a minimum thickness near their centre and a maximum thickness near 30 their edges, this variation apparently being derived from the meniscus effect of the composition at the side walls of the mould. The variation in thickness had disadvantages, for example, in handling the formed article and in obtaining consistent and minimal drying times in their preparation. It is an object of the present invention to alleviate these disadvantages.
Accordingly the present invention provides a process for preparing a solid shaped article carrying a predetermined unit quantity of a chemical which process comprises adding to a mould a composition comprising the predetermined amount of chemical and a solution in a solvent of a carrier material inert towards the chemical, the side wall or walls of the mould diverging outwards from the base and making an angle with the vertical of at least 5' at the surface of the composition and the mean depth of the composition in the mould being about 40 4.0 mm or less, freezng the composition in the mould and then subliming solvent from the frozen composition so as to produce a network of carrier material carrying the chemical.
Preferably the side wall or walls slope outwardly from a substantially flat base and make a constant angle with the vertical, the angle being at least 5. However, the side walls need not make a constant angle provided that the angle is at least 5 at the surface of the composition. 45 For example the angle below the surface may be less than that at the surface. In addition, or alternatively, the angle above the surface could be greater than the angle at the surface.
The mould is preferably a depression in a sheet of filmic material as hereinabove described.
The chemical may be any chemical (including, for example, agricultural or horticultural chemicals or chemical reagents) which it is desired to administer, dispense or utilise in predetermined unit quantities. Preferably the chemical is a pharmaceutical substance and the solid shaped article carring the predetermined unit quantity of pharmaceutical substance is a pharmaceutical dosage form, particularly a pharmaceutical dosage form suitable for oral administration. By choice of a carrier material that is water soluble or water dispersible it is possible to prepare shaped articles, including pharmaceutical dosage forms, that are capable of 55 being rapidly disintegrated by water, for example, within ten seconds (or preferably 5 seconds) when tested by, for example, the test procedure described in the above mentioned specifica tions. Examples of suitable carrier materials are given in the above mentioned specifications. For example, the carrier may be formed from polypeptides such as gelatin, particularly gelatin which is partially hydrolysed, e.g. by heating in water. For example, the gelatin may be partially 60 hydrolysed by heating a solution of the gelatin in water, e.g. in an autoclave at about 1 2WC for up to 2 hours, e.g. from about 5 minutes to about 1 hour, preferably from about 30 minutes to about 1 hour. The hydrolysed gelatin is preferably used at concentrations of about 1 to 6% weight/vol., most preferably at 2 to 4% e.g. about 3%. Other carrier materials may be used in place of partially hydrolysed gelatin for example polysaccharides such as hydrolysed dextran, 65 2 GB2119246A 2 TABLE 1
Profile Diameter Depth of Upper Capacity Angle of 45 at base depression diameter (M1) side wall (MM) (MM) (MM) to the vertical 1 12.0 3 13.0 0.36 9.5 50 2 11.5 3 13.0 0.35 14.0' 3 11.0 3 13.0 0.34 18.5' 4 10.0 3.5 14.6 0.41 33.0 9.0 3.5 14.8 0.39 39.5 6 14.2 3.5 15.0 0.59 6.5 55 control 14.4 6.0 15.0 1.0 2 ' An aqueous composition having the following constitution was prepared:
3% hydrolysed gelatin 3% mannitol B.P.
(The 3% hydrolysed gelatin is prepared by suspending 30 g. of powdered gelatin in 800 mi of water, autoclaving it at 121 'C for 60 minutes and adjusting the final volume to 1 litre).
Varying amounts of the composition with and without the addition of a surfactant (1 % Tween 80) were added to the depressions (i.e. moulds) of Table 1. The compositions were then frozen 65 dextrin and alginates (e.g. sodium alginate) or mixtures of above mentioned carriers with each other or with other carrier materials such as polyvinyl alcohol, polyvinylpyrrolidine or acacia.
Besides the chemical and the carrier material the composition may contain other additional ingredients. For example, when preparing pharmaceutical dosage forms the composition may include pharmaceutical ly acceptable adjuvants such as colouring agents, flavouring agents, preservatives and the like. In addition the composition may contain ingredients which aid in the preparation of the shaped articles. For example, the composition may include a surfactant, e. g. Tween 80 [polyoxyethylene (20) sorbitan mono-oleate], to aid in the dispersion of the chemical. The composition may also include ingredients such as fillers (e.g. mannitol, sorbitol) which improve the physical properties of the shaped article.
The solvent for the composition is preferably water but is may contain a co-solvent (such as an alcohol) if it is desired to improve the solubility of the chemical.
The ingredients for the composition may be filled into the mould individually or in admixture, preferably as a mixture comprising the complete composition.
The volume of the composition in the mould is preferably about 3 mi or less (for example, 15 about 0.25 to 1 m]) especially when the shaped article is a pharmaceutical dosage form for oral administration. The depth of the composition in the mould, the cross sectional area of the mould and the angle of the side wall or walls will all affect the volume of the composition. The mould can be, for example, a regular shape such as a circle or a polygon (e.g. a rectangle particularly a square) in horizontal cross section with the area of the section at the base of the mould being 20 less than the area nearer the open top, in view of the sloping sides. Preferably the mould is circular in cross section and the formed shaped article resembles a flat disc having sloping side walls.
In order to keep drying times in the freeze dryer to a minimum it is preferable that the depth of composition in the mould should be less than 3.5 mm, for example, 1.5 (or more preferably 25 2) to 2.5 mm. If the depth is below about 1.5 mm the shaped articles tend to be difficult to handle.
The invention further provides a shaped article produced by the process of the invention. The invention particularly provides a solid shaped article produced by freezing a composition comprising a predetermined amount of chemical and a solution in a solvent of a carrier material 30 inert towards the chemical and subliming solvent from the frozen composition so as to produce a network of carrier material carrying the chemical characterised in that the shaped article has a mean thickness of about 4.0 mm or less and has side wall or walls diverging outwards from a bottom surface, said side walls making an angle with the vertical of at least 5' at the upper surface.
In order to investigate the effect of the angle of the side wall or walls had on the variations in thickness of the formed shaped article, a number of blister trays were thermoformed from 200ja UPVC having depressions in them of varying profiles. The depressions were circular in cross section and the profiles, in general, were of inverted truncated cone shape with the side walls making various angles with the vertical. The dimensions of the different profiles together with 40 that of a conventionally formed flat base blister pack (control) are given below:- 0 3 GB2119246A 3 and the solvent sublimed in a freeze dryer to give solid shaped articles, samples of which, when tested by the procedure in the aforementioned specifications, disintegrated rapidly in water. The dimensions of the shaped articles were determined using a micrometer system and the variation in thickness of the individual samples were calculated. The mean maximum thickness variation for the different samples is shown in the following Table 11 and is illustrated graphically in Fig. 1 5 ofthe accompanying drawings.
TABLE 11
Pro,ile Angle of side Mean maximum 10 wall to the thickness vertical variation (mm) 1 9.51 0.8 2 14.0' 0.57 15 3 18.51 0.4 4 33.0' 0.48 39.5' 0.42 6 6.5' 1.07 Control 2 1.88 20 The results show that there was considerable variation in thickness of the samples when the side walls of the mould approached the vertical as, for example in the control. The maximum thickness was at the edge and the minimum thickness was at the centre in these samples, this 25 variation being apparently derived from the meniscus effect although it was not significantly affected by the presence of surfactant. The articles made in depressions in which the side walls made angles with the vertical of considerably more than 5' had much flatter top surfaces. In many of these latter cases the small variation in thickness that did occur was the result of an increased thickness in the centre (a---blip---)apparently produced during the freezing procedure., 30 The variations in thickness due to the meniscus effect could be avoided by filling the moulds completely to their upper surface, but, using such full moulds can give rise to further difficulties in that there can be spillage during filling or when the moulds are subsequently handled while the contents are still liquid. In addition, further difficulties can arise if a cover layer is applied over the freeze dried articles in the moulds; the articles may stick to the cover layer if their upper 35 surfaces are substantially level with the upper surfaces of the moulds. In the present invention a mould is used in which the side wall or walls make an angle with the vertical of at least 5'. The angle with the vertical may be, for example, from 5' to about 40, and the advantage of minimal thickness variation is retained. Especially preferred angles for this 40 advantage as shown in the above profiles, are from about 9 to 40'. However, if the side walls 40 make too big an angle with the vertical the moulds waste unnecessary space in the freeze drier and also the products produced have sharp edges which make them difficult to handle. Accordingly it is preferred that the angle made with the vertical is within the range 9' to 20, for example 10 to 15'. A particularly preferred angle is about 12'. 45 The following Examples illustrate the invention:
EXAMPLE 1 Pharmaceutical Dosage Forms containing 15 mg oxazepam Formulation:
Oxazepam Tween 80 BPC Mannitol BP 15mg 0.25mg 15mg 3% hydrolysed gelatin to 0.5mi The 3% hydrolysed gelatin is prepared by suspending 30 g of powdered gelatin in 800 m] of cold distilled water in a 1 litre flask and autoclaving it at 121 'C for 60 minutes. When cool, the final volume is adjusted to 1 litre.
Oxazepam (30 g) is suspended in 3% hydrolysed gelatin solution containing dissolved mannitol (30g) and Tween 80 (0.5 g) using ultrasonics for 5 minutes and the suspension made 60 up to 1 litre with 3% gelatin solution. 0.5 mi portions of the suspension are dosed, using an automatic filling machine, into pockets in polyvinyl chloride blister trays. Each of the pockets in the blister tray is of inverted truncated conical shape of 3.5 mm depth, a bottom diameter of 14.5 mm and a top diameter of 16 mm (i.e. the sides walls make an angle with the vertical of about 12'). The contents of the pockets are then frozen by passing the trays through a freeze 65 4 GB2119246A 4 tunnel into which liquid nitrogen is injected.
The blister trays containing the frozen compositions are then transferred to a freeze drier. The pressure is adjusted to 0.5 mm Hg. The temperature of the shelves in the freeze drier is set at WC for 1 hour and then lowered to 4WC. After 2 hours the trays are removed from the freeze drier. A peelable aluminium foil is then sealed to the blister pack around the depressions containing the pharmaceutical dosage forms. The pharmaceutical dosage forms are of substantially uniform thickness and disintegrate rapidly, for example, in two seconds or less, when taken orally.
EXAMPLES 2 TO 11 The procedure of Example 1 is followed to prepare pharmaceutical dosage forms containing the following active ingredients:
Example
2 Oxazepam 30 mg and 50 mg 15 3 Lorazepam 1, 2, 2.5 and 4 mg 4 Temazepam 10 and 20 mg Lormetazepam 1 mg 6 Frusemide 40 mg 7 Bendrofluazide 5 mg 20 8 Cyclopenthiazide 0.5 mg 9 Isosobide dinitrate 2.5, 5 and 10 mg Indomethacin 25 and 50 mg 11 Prochlorperazine maleate 50 mg 25 EXAMPLE 12 - Formulation:
Indole acetic acid Mannitol BP 1 5mg 3% hydrolysed gelatin to 0.5mi The procedure of Example 1 is followed substituting 29 of indole acetic acid for the 309 of oxazepam and omitting the Tween 80. Each of the resulting freeze dried products can be added to 1 litre of water to give a composition useful as a plant growth promoter.
EXAMPLE 13 The procedure of Example 12 is repeated replacing the indole acetic acid by indole butyric acid. Each of the freeze dried products containing 1 mg of indole butyric acid may be added to 1 litre of water to give a composition useful as a rooting growth promoter for plant cuttings.

Claims (16)

1. A process for preparing a solid shaped article carrying a predetermined unit quantity of a chemical which process comprises adding to a mould a composition comprising the predeter- mined amount of chemical and a solution in a solvent of a carrier material inert towards the chemical, the side wall or walls of the mould diverging outwards from the base and making an angle with the vertical of at least 5' at the surface of the composition and the mean depth of the composition in the mould being about 4.0 mm or less, freezing the composition in the mould and then subliming solvent from the frozen composition so as to produce a network of carrier material carrying the chemical.
2. A process as claimed in Claim 1 wherein the volume of the composition in the mould is about 3 mi or less.
3. A process as claimed in claim 1 wherein the volume of the composition in the mould is about 0.25 to 1 mi.
4. A process as claimed in any one of the preceding claims wherein the depth of the composition in the mould is less than 3.5 mm.
5. A process as claimed in any one of the preceding claims wherein the depth of the composition in the mould is 1.5 to 2.5 mm.
6. A process as claimed in any one of the preceding claims wherein the angle with the vertical is from 9' to 20'.
7. A process as claimed in any one of the preceding claims wherein the angle with the vertical is from 10' to 15'.
8. A process as claimed in any one of the preceding claims wherein the mould is a depression in a sheet of filmic material.
9. A process as claimed in any one of the preceding claims wherein the carrier material is 65 GB2119246A 5 hydrolysed gelatin.
10. A process as claimed in any one of the preceding claims wherein the chemical is a pharmaceutical substance and the solid shaped article is a pharmaceutical dosage form.
11. A solid shaped article produced by freezing a composition comprising a predetermined amount of chemical and a solution in a solvent of a carrier material inert towards the chemical and subliming solvent from the frozen composition so as to produce a network of carrier material carrying the chemical characterised in that the shaped article has a mean thickness of about 4.0 mm or less and has side wall or walls diverging outwards from a bottom surface, said side walls making an angle with the vertical of at least 5' at the upper surface.
12. A solid shaped article as claimed in claim 11 wherein the carrier material is hydrolysed 10 gelatin.
13. A solid shaped article as claimed in claim 11 or 12 wherein the chemical is a pharmaceutical substance.
14. A solid shaped article whenever prepared by the process claimed in any one of claims 1 to 10.
15. A solid shaped article substantially as hereinbefore described with reference to any one of the Examples.
16. A process for preparing a solid shaped article substantially as hereinbefore described with reference to any one of the Examples.
Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd.-1 983. Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.
GB08232189A 1981-12-02 1982-11-11 Solid shaped articles Expired GB2119246B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8136360 1981-12-02

Publications (2)

Publication Number Publication Date
GB2119246A true GB2119246A (en) 1983-11-16
GB2119246B GB2119246B (en) 1985-05-22

Family

ID=10526336

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08232189A Expired GB2119246B (en) 1981-12-02 1982-11-11 Solid shaped articles

Country Status (41)

Country Link
US (1) US4758598A (en)
EP (1) EP0081912B1 (en)
JP (1) JPS58113123A (en)
KR (1) KR880001206B1 (en)
AR (1) AR229543A1 (en)
AT (1) ATE27058T1 (en)
AU (1) AU554816B2 (en)
BR (1) BR8206982A (en)
CA (1) CA1200960A (en)
CS (1) CS238637B2 (en)
CY (1) CY1326A (en)
DD (1) DD206534A1 (en)
DE (1) DE3276260D1 (en)
DK (1) DK159797C (en)
DO (1) DOP1982004083A (en)
DZ (1) DZ481A1 (en)
EG (1) EG15502A (en)
ES (1) ES8401720A1 (en)
FI (1) FI77155C (en)
GB (1) GB2119246B (en)
GR (1) GR77773B (en)
HK (1) HK19586A (en)
HU (1) HU187802B (en)
IE (1) IE53696B1 (en)
IL (1) IL67266A (en)
IN (1) IN157896B (en)
JO (1) JO1225B1 (en)
KE (1) KE3601D (en)
MA (1) MA19658A1 (en)
MX (1) MX195411A (en)
MY (1) MY8600502A (en)
NO (1) NO159060C (en)
NZ (1) NZ202482A (en)
PH (1) PH18441A (en)
PL (1) PL139503B1 (en)
PT (1) PT75923B (en)
SA (1) SA91110229B1 (en)
SU (1) SU1514239A3 (en)
YU (1) YU43727B (en)
ZA (1) ZA828371B (en)
ZW (1) ZW25282A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404490A1 (en) * 1989-06-20 1990-12-27 American Home Products Corporation Fast dissolving dosage forms
US5631023A (en) * 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
EP2322194A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
DE20321887U1 (en) 2003-11-10 2012-01-20 Allergan, Inc. Medicines comprising low doses of desmopressin

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950689A (en) * 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
US5215756A (en) * 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
DK0617613T3 (en) * 1991-12-20 1996-06-17 Pfizer Porous shaped delivery devices and method of making them
WO1993013757A1 (en) * 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US5876754A (en) * 1992-01-17 1999-03-02 Alfatec-Pharma Gmbh Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US5271874A (en) * 1992-11-04 1993-12-21 Wesley-Jessen Corporation Method for molding a hydrophilic contact lens
CA2134611C (en) * 1994-10-28 2002-12-24 Richard John Yarwood Process for preparing solid pharmaceutical dosage forms
US5837287A (en) * 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
GEP20012374B (en) * 1995-03-02 2001-03-25 Scherer Ltd R P Pharmaceutical Compositions Comprising Monoamine Oxidase B Inhibitors, Method for Obtaining the Same and Use
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
PL188231B1 (en) 1996-06-17 2004-12-31 Janssen Pharmaceutica Nv Biconvex drug administration forms rapidly undergoing disintegration
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1079808B1 (en) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
HUP0105089A3 (en) 1998-11-20 2002-09-30 Skyepharma Canada Inc Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
JP4042394B2 (en) * 2001-12-04 2008-02-06 味の素株式会社 Manufacturing method of block-like freeze-dried foods
EP1551373B1 (en) * 2002-10-16 2014-11-12 MedSkin Solutions Dr. Suwelack AG Use of molded bodies for external application
US20040234579A1 (en) * 2003-05-22 2004-11-25 Mark D. Finke, Inc. Dietary supplements and methods of preparing and administering dietary supplements
ES2386616T3 (en) 2009-04-22 2012-08-23 Dr. Suwelack Skin & Health Care Ag Lyophilized molded body containing magnesium ascorbyl phosphate
BRPI1001091A2 (en) 2009-04-22 2011-03-22 Dr Suwelack Skin & Health Care Ag freeze-dried coated molded article
MA34262B1 (en) * 2010-05-31 2013-05-02 Haremlik Gida Dekorasyon Ve Ekipmanlari Ticaret Sanayi Ltd Sirketi CAPSULE FOR THE PAYMENT OF A POWDER IN A DEVICE
WO2014100418A2 (en) 2012-12-20 2014-06-26 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
BR112020015253A2 (en) 2018-03-08 2020-12-08 Catalent U.K. Swindon Zydis Limited PROCESS TO REDUCE ENDOTOXIN IN GELATINE
EP3814709A1 (en) * 2018-06-29 2021-05-05 Universiteit Gent Freezing, drying and/or freeze-drying of product dose units
AR118159A1 (en) 2019-02-22 2021-09-22 Catalent Uk Swindon Zydis Ltd MINIMIZATION OF AGGLOMERATION, AERATION AND PRESERVATION OF THE COATING OF PHARMACEUTICAL COMPOSITIONS INCLUDING IBUPROFEN
PL3927314T3 (en) 2019-02-22 2024-02-19 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
PL3927312T3 (en) 2019-02-22 2024-02-26 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
EP3996695A4 (en) * 2019-08-12 2023-03-15 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
US11173114B1 (en) 2020-07-10 2021-11-16 Nova Thin Film Pharmaceuticals Llc Method and system for manufacturing and oral soluble films and oral soluble films made by thereby
CN117412672A (en) * 2021-06-02 2024-01-16 揖斐电株式会社 Powdered plant activator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE709590A (en) * 1967-01-24 1968-05-30
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) * 1977-07-20 1981-03-10 George K. E. Gregory Packages

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0404490A1 (en) * 1989-06-20 1990-12-27 American Home Products Corporation Fast dissolving dosage forms
US5631023A (en) * 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
EP2322194A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
EP2322195A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
EP2322197A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
EP2322198A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
EP2322196A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
DE20321887U1 (en) 2003-11-10 2012-01-20 Allergan, Inc. Medicines comprising low doses of desmopressin

Also Published As

Publication number Publication date
KR840002651A (en) 1984-07-16
DZ481A1 (en) 2004-09-13
KR880001206B1 (en) 1988-07-11
NO824023L (en) 1983-06-03
ATE27058T1 (en) 1987-05-15
YU265582A (en) 1985-03-20
PL139503B1 (en) 1987-01-31
HK19586A (en) 1986-03-27
AU554816B2 (en) 1986-09-04
FI823983A0 (en) 1982-11-19
PT75923A (en) 1982-12-01
ZA828371B (en) 1984-06-27
GB2119246B (en) 1985-05-22
YU43727B (en) 1989-10-31
EG15502A (en) 1986-12-30
DOP1982004083A (en) 1988-03-21
JO1225B1 (en) 1985-04-20
CY1326A (en) 1986-06-27
IL67266A0 (en) 1983-03-31
IE822663L (en) 1983-06-02
GR77773B (en) 1984-09-25
MA19658A1 (en) 1983-07-01
EP0081912A3 (en) 1984-07-11
PT75923B (en) 1985-01-25
PL239301A1 (en) 1983-08-15
FI77155C (en) 1989-02-10
SA91110229B1 (en) 2003-02-24
FI823983L (en) 1983-06-03
JPS58113123A (en) 1983-07-05
MX195411A (en) 1993-11-01
AU9061882A (en) 1983-06-09
IL67266A (en) 1985-06-30
BR8206982A (en) 1983-10-11
ES517853A0 (en) 1984-01-01
NO159060B (en) 1988-08-22
ZW25282A1 (en) 1984-06-20
DK159797B (en) 1990-12-03
NO159060C (en) 1988-11-30
DE3276260D1 (en) 1987-06-11
DD206534A1 (en) 1984-02-01
EP0081912B1 (en) 1987-05-06
NZ202482A (en) 1985-08-30
JPH0149242B2 (en) 1989-10-24
MY8600502A (en) 1986-12-31
US4758598A (en) 1988-07-19
ES8401720A1 (en) 1984-01-01
IE53696B1 (en) 1989-01-18
EP0081912A2 (en) 1983-06-22
FI77155B (en) 1988-10-31
CS238637B2 (en) 1985-12-16
SU1514239A3 (en) 1989-10-07
CA1200960A (en) 1986-02-25
PH18441A (en) 1985-07-08
AR229543A1 (en) 1983-09-15
KE3601D (en) 1986-02-14
DK159797C (en) 1991-05-06
DK532682A (en) 1983-06-03
IN157896B (en) 1986-07-19
HU187802B (en) 1986-02-28

Similar Documents

Publication Publication Date Title
US4758598A (en) Solid shaped articles
EP0084705B1 (en) Process for preparing solid shaped articles
EP0404490B1 (en) Fast dissolving dosage forms
US5827541A (en) Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
CA1097233A (en) Packages
CA2134611C (en) Process for preparing solid pharmaceutical dosage forms
KR100194241B1 (en) Pharmaceutical forms and other dosage forms
GB2111423A (en) Moulding quick-dissolving dosage units
CA2023200A1 (en) A new freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB2138290A (en) Divisible polyacrylate-based tablet
EP3919616A1 (en) Cell carrier particulate aggregate and preparation method thereof
GB2328154A (en) A method of tabletting comprising forming a mixture, containing active agent & free-flowing ice particles, into a tablet & removing the ice from the tablet
DD206534A5 (en) METHOD FOR PRODUCING A SOLID SHAPED OBJECT

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20021110